Fact-check: “The benefits of GLP-1 outweigh the potential side effects.”
Verdict: Partly True (70% confidence)
Note (contested-claim adjustment): within the retrieved evidence, FDA Approved Labeling — Zepbound (tirzepatide), 2026-04-24; Wegovy (semaglutide) label, 2023-11-08 and PubMed (NCBI), published 2022-12-28 disputes the position this verdict leans toward. Definitive language in this analysis (e.g. "documented", "proven") should be read as asserted by the cited sources and disputed by FDA Approved Labeling — Zepbound (tirzepatide), 2026-04-24; Wegovy (semaglutide) label, 2023-11-08 and PubMed (NCB…
This fact-check was conducted by SpinkillerAI, a non-partisan AI-powered accountability platform.
Related fact-checks
- Medicare for all would cost trillions a year that Americans would pay through higher income taxes — Partly True
- There is a 10% possibility that ai will end humans in 10 years — Partly True
- Interest rates should come down when the war ends — Partly True
- China is sending armament to Iran for its conflict with the US — Mostly True
- In this economy bonds are a safer investment — Misleading